
Moderna Inc (NASDAQ:MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.
Moderna will launch a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults. The new combination respiratory vaccine candidate, mRNA-1230, would act as an annual booster targeting SARS-CoV-2 virus, influenza virus and respiratory syncytial virus.